


The Compliment System

- The complement system is the major effector of the humoral branch of the immune system.
- Research on complement started in 1890s.
- Julius Bordet at the Institute Pasteur observed that sheep antiserum to the bacterium *Vibrio cholerae* caused lysis of the bacteria & heating the antiserum destroyed its bacteriolytic ability.
- Surprisingly, the ability to lyse the bacteria was restored to the heated serum by adding fresh serum that contained no antibodies directed against the bacterium & by itself was unable to kill it.

- Bordet accurately concluded that bacteriolytic activity requires two different substances:
- i) the specific antibacterial antibodies, which survive the heating process &
- ii) heat sensitive component responsible for the lytic activity.
- Bordet devised a simple test for the lytic activity, the easily detected lysis of antibody coated RBCs, called haemolysis.
- Shortly afterwards in Berlin, Paul Ehrlich independently carried out similar experiments & coined the term complement, defining it as ‘the activity of blood serum that completes the action of antibody’.

- The functions of complement:
- Research on complement now includes more than 30 soluble & cell bound proteins.
- After initial activation, the various complement components interact in a highly regulated cascade, to carry out a number of basic functions, including,
 - - Lysis of cells, bacteria & viruses.
 - - Opsonization, which promotes phagocytosis of particulate antigen.
 - - Binding to specific complement receptors on cells of the immune system, triggering activation of immune responses.

- Immune clearance, which removes immune complexes from the circulation & deposits them in the spleen & liver.



- The complement components:
- The proteins & glycoproteins of the complement system are synthesized mainly by liver hepatocytes.
- Significant amount of them are also produced by blood monocytes, tissue macrophages & epithelial cells of & the GI & urinogenital tracts.
- These constitute 5% of the serum globulin fraction & most circulate in the serum in the free inactive form.
- Many components are proenzymes or zymogens, which are inactive until proteolytic cleavage, which removes an inhibitory fragment & exposes the active site.

- The reaction sequence starts with an enzyme cascade.
- Several of the activated components become inactivated shortly if they do not react with the next component in the sequence.
- Complement components are designated by -
 - - numerals c1 – c9.
 - - letter symbols, eg. Factor D.
 - - or by names, eg. Homologous restriction factor.
- The peptide fragments formed by activation of component are denoted by small letters.


- In most cases, the smaller fragment is designated 'a' & a larger one 'b', eg. c3a, c3b.
- c2 is an exception where c2a is the larger fragment.
- The larger fragment bind to the target near the site of activation.
- The smaller fragment diffuse from the site & can initiate localized inflammatory responses by binding to specific receptors.
- The complement fragments interact with one another to form functional complexes.
- Complexes having enzymatic activity are designated by a bar over the number or symbol, eg. c4b2a, c3bBb.

- The model traditionally used to explain c activity is the lysis of erythrocyte sensitized by its antibody.
- The erythrocyte (E) – antibody (A) complex is called as EA.
- When c components are attached to EA, the product is called EAC, followed by the component that have reacted, eg. EAC12345 or EAC1-5.

- Complement activation:
- Complement is normally present in the body in an inactive form.
- When its activity is induced by Ag-Ab stimuli, C components react in a specific sequence as a cascade.
- C cascade is a series of reactions in which the preceding component acts on succeeding components, cleaving them into dissimilar fragments.
- The C cascade can be triggered by three parallel but independent mechanisms or pathways which differ only in the initial steps.


- Once c3 activation occurs, the subsequent steps are common in all pathways,
- - the classical pathway &
- - the alternative pathway or properdin pathway
- - the lectin pathway.

Complement System: Overview



- The classical pathway:
- The chain of events in which C components react in a specific sequence following activation of C1 & typically culminates in cytolysis is known as the classical pathway.
- It consists of the following steps:
- 1) The first step is the binding of C1 to the Ag-Ab complex, traditionally represented EA.
- C1 in serum is a macromolecular complex consisting of C1q & two molecules each of C1r & C1s, held together in a complex (C1qr₂s₂) stabilized by calcium ions.



Structure of the C1 macromolecular complex




C1q molecule



- c1q is the recognition unit of c1 & reacts with the Fc piece of IgM or IgG.




- c1q has six combining sites.
- Effective activation occurs only when c1q is attached to immunoglobulins by at least two of its binding sites.
- One molecule of IgM or two molecules of IgG can therefore initiate the process.






IgM

Vs





IgG


ANTIBODY CLASSIFICATION




IgM



- c1q binding in the presence of calcium ions leads to sequential activation of c1r & c1s.
- 2) Activated c1s is an esterase, one molecule of which can cleave several molecules of c4.
- c4 is split into c4a which is an anaphylatoxin & c4b which binds to cell membrane along with c1.




- 3) c4b in the presence of magnesium ions cleave c2 into c2a which remains linked to cell bound c4b & c2b which is released into fluid phase.




c4b2a has enzymatic activity & is known as classical pathway C3 convertase.

- 4) c3 convertase splits c3 into two fragments,



- c3a is an anaphylatoxin which is released into the medium.
- c3b which remains cell bound along with c4a2b to form a trimolecular complex c4b2a3b has enzymatic activity & is called c5 convertase.


- 5) The membrane attack phase of complement activity begins at this stage with c5 convertase, converting c5 into,



- c5a is an anaphylatoxin which is released into the medium.
- c5b continues the cascade.
- c6 & c7 then join together.
- A heat stable trimolecular complex is formed c5b67.

- A part of C5b67 binds to the cell membrane & prepare it for lysis by C8 & C9 which join the reaction subsequently.
- Most of the C5b67 escape & serve to amplify the reaction by absorbing unsensitized cells & rendering them susceptible to lysis by C8 & C9.
- The mechanism of complement mediated cytolysis

Antigen-Antibody



The Classical Pathway

EA-----c1q1r1s -----(Ca+)------EAc1

c4 → a,b

EAc14b-----c2 → a,b---(Mg+)------EAc14b2a → c2b

c4a

c3 → a,b

EAc14b2a3b-----c5 → a,b-----EAc14b2a3b5b67

c3a

c5a

c8,9

EAc14b2a3b5b6789


CYTOLYSIS

The Classical Pathway

- Alternative pathway:
- The central process in the complement cascade is the activation of c3, which is the major component of c.
- In the classical pathway, activation of c3 is achieved by c42 (classical c3 convertase).
- The activation of c3 without prior participation of c142 is known as the alternative pathway.
- The first example of the alternative pathway was the demonstration by Pillemer (1954).
- He demonstrated properdin system as a group of serum proteins contributing to antibacterial defence without requiring specific antibodies.

- The activator in this system was zymosan, a polysaccharide from the yeast cell wall, but many other substances can also activate the pathway.
- These activators include bacterial endotoxins, IgA & D, the cobra venom factor & the nephritis factor (a protein present in the serum of glomerulonephritis patients).
- 1) The first step in the alternative pathway is the binding of c3b to an activator.
- c3b is continuously generated in small quantities in the circulation.
- But in free state, it is rapidly inactivated by the serum protein factors H & I.

- Bound c3b is protected from such inactivation.
- 2) It interacts with a serum protein called factor B (also known as c3 proactivator) to form a magnesium dependent complex c3bB.
- This complex is cleaved by another serum protein factor D (also known as c3 proactivator convertase) into two fragments Ba & Bb.



- Fragment Ba is released into the medium.

- 3) Fragment Bb remains bound to c3b, forming the esterase c3bBb complex, which is the alternative pathway c3 convertase.
- This enzyme c3bBb is extremely labile.
- The function of properdin (also called factor P) is to stabilize the c3 convertase.
- c3bBb hydrolyses c3 leading to further steps in the cascade as in the classical pathway.

- C3b in circulation

Free c3b inactivated by factors H & I

Stabilized when combined with activator, eg. Zymosan

c3b + Factor B

c3b B + (Factor D)


Ba

c3bBb + (Properdin)


c3b Bb P + c3

The Alternative pathway

Cascade



Alternative



Initiators of the alternative pathway of complement activation:

PATHOGENS AND PARTICLES OF MICROBIAL ORIGIN:

- i) Many strains of gram-negative bacteria
- ii) Lipopolysaccharides from gram-negative bacteria
- iii) Many strains of gram-positive bacteria
- iv) Teichoic acid from gram-positive cell walls
- v) Fungal and yeast cell walls (zymosan)
- vi) Some viruses and virus-infected cells
- vii) Some tumor cells (Raji)
- viii) Parasites (trypanosomes)

NONPATHOGENS:

- i) Human IgG, IgA, and IgE in complexes
- ii) Rabbit and guinea pig IgG in complexes
- iii) Cobra venom factor
- iv) Heterologous erythrocytes (rabbit, mouse, chicken)
- v) Anionic polymers (dextran sulfate)
- vi) Pure carbohydrates (agarose, inulin)

- The Lectin pathway:
- Recently, an additional means by which the complement cascade can be activated was described.
- This is known as lectin pathway.
- Lectins are proteins that bind to a carbohydrate.
- The lectin pathway, like the alternative pathway, does not depend on antibody for its activation.
- However, the mechanism is more like that of the classical pathway.
- Because, after initiation, it proceeds through the action of C4 & C2, to produce a C5 convertase.

- The pathway is activated by the binding of mannose-binding lectin (MBL) to mannose residues on glycoproteins or carbohydrates on the surface of microorganisms.
- MBL is an acute phase protein produced in inflammatory responses.
- Its function in the complement pathway is similar to that of C1q, which it resembles in structure.
- 1) First MBL binds to the surface of a cell or pathogen.
- 2) Then, MBL-associated serine protease (MASP) binds to it.

- 3) The active complex formed by this association causes cleavage & activation of c4.
- MASP has structural similarity to c1r & c1s & mimics their activities.
- Details of the lectin pathway remain obscure, but this way of activating the c2 – c4 components to form a c5 convertase without need for specific antibody binding certainly represents an important innate defence mechanism comparable to the alternative pathway.




FIG. 15-5. Lectin pathway of activation of the complement.

**CLASSICAL
PATHWAY**

Immune complexes

**LECTIN
PATHWAY**

Carbohydrates,
Collectins

**ALTERNATIVE
PATHWAY**

Activating surfaces

C1q

C1r
C1s
C4
C2

MBP

MASP
C4
C2

C1r
C1s
C4
C2

C3b


P
D
B

C3

C3b

C5b678(9)_n

(MAC)



- Terminal sequence- Formation of Membrane Attack Complex:
- The terminal sequence of complement activation involves c5b, c6, c7, c8 & c9.
- These interact sequentially to form a macromolecular structure called the membrane attack complex (MAC).
- This complex displaces the membrane phospholipids, forming a large transmembrane channel that disrupts the membrane of the target cell & enables ions & small molecules to diffuse through it freely.


- The c5b component is extremely labile & is inactivated within two minutes unless c6 binds to it & stabilizes its activity.
- Up to this level, all complement reactions take place on the hydrophilic surface of membrane or on immune complexes in the humoral system.
- As c5b6 binds to c7, the resulting complex undergoes a hydrophilic- amphiphilic structural transition that exposes hydrophobic regions.
- These serve as binding sites for membrane phospholipids.
- This site enable c5b67 complex to insert into the phospholipid bilayer.

- Binding of c8 to this c5b67 complex induces a conformational change in c8.
- It also undergoes the hydrophilic- amphiphilic structural transition exposing a hydrophobic region which interacts with the plasma membrane.
- The c5b678 complex creates a small pore, 10 Å⁰ in diameter.
- Formation of this pore can lead to lysis of RBCs but not of nucleated cells.
- Final step is the binding & polymerization of c9 to the c5b678 complex.
- As many as 10-17 molecules of c9 can be bound & polymerized by a single c5b678 complex.

- During polymerization, the c9 molecules also undergo hydrophilic- amphiphilic transition so that they can be inserted into the membrane.
- The completed MAC has a tubular form & function pore size of 70-100 Å.rough this
- It consists of a c5b678 complex surrounded by a poly c9 complex.
- Since ions & small molecules can diffuse freely this, the cell cannot maintain its osmotic stability & is killed by an influx of water & loss of electrolytes.

Schematic diagram of intermediates in the classical pathway of complement activation (5).



C5b binds C6, initiating the formation of the membrane-attack complex.



The MAC complex forms a large channel through the membrane of the target cell, enabling ions and small molecules to diffuse freely across the membrane.

C9: a perforin-like molecule

C5b triggers formation of the Membrane Attack Complex



MAC is most effective against
Gram-negative bacteria
Nucleated cells
Enveloped viruses

CD59 prevents assembly of the membrane attack complex on human cells




Figure 2.14 The Immune System, 4th ed. (© Garland Science 2015)